Cellular and Molecular Life Sciences CMLS

, Volume 63, Issue 23, pp 2773–2791 | Cite as

Direct thrombin inhibitors – a survey of recent developments

  • A. Schwienhorst


Thrombin is a plasma serine protease that plays a key role in coagulation and hemostasis but also in thromboembolic diseases. Direct thrombin inhibitors could, therefore, be beneficial for future anticoagulant therapy in the prophylaxis of venous and arterial thrombosis as well as myocardial infarction. However, development of direct thrombin inhibitors has brought researchers more heartache than success. The most recent setback came this year when AstraZeneca withdrew Ximelagatran, the first orally bioavailable direct thrombin inhibitor that had received regulatory approval (France, 2003), after reports of serious hepatoxicity in a fraction of patients. This review describes the status of direct thrombin inhibitors, focusing on drug candidates that are at present in clinical trials. In addition, some more recent research strategies in the design of novel direct thrombin inhibitors are discussed, which may very well contribute to future developments of potent anticoagulants.


Direct thrombin inhibitor hirudin anticoagulant therapy thromboembolic disease drug candidate oral bioavailability neutral P1 moiety 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, Basel 2006

Authors and Affiliations

  1. 1.Department of Molecular Genetics and Preparative Molecular BiologyInstitute for Microbiology and GeneticsGoettingenGermany

Personalised recommendations